Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hidenobu Harada currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by a distinct examiner in a distinct art unit. The busiest examiner for this portfolio is BURKHART, MICHAEL D, who is responsible for the 1 pending office action. For practitioners, this indicates a highly concentrated prosecution effort with no current distribution across multiple examiners or art units.
The focus on a single art unit suggests a specific technological niche within the broader Biotechnology & Pharmaceuticals field. Because only a single examiner is involved, the outcome of the current portfolio depends entirely on the interactions with BURKHART, MICHAEL D. This lack of examiner diversity means there are no other pending matters to provide comparative insights into different examination styles for this applicant. Success in this instance relies on navigating the unique requirements of the assigned art unit without the benefit of broader portfolio trends.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18851407 | METHOD FOR THAWING BIOLOGICALLY-DERIVED FROZEN MATERIAL BY VERY HIGH FREQUENCY ELECTROMAGNETIC WAVE IRRADIATION, CRYOPRECIPITATE PRODUCING METHOD, AND THAWING DEVICE | BURKHART, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851407 | METHOD FOR THAWING BIOLOGICALLY-DERIVED FROZEN MATERIAL BY VERY HIGH FREQUENCY ELECTROMAGNETIC WAVE IRRADIATION, CRYOPRECIPITATE PRODUCING METHOD, AND THAWING DEVICE | BURKHART, MICHAEL D | 1638 | §103 | Non-Final OA | — | Pending | Sep 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHidenobu Harada has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Burkhart has the most, with 1 of Hidenobu Harada's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
